Sign In
Buy HROW
$41.81
-0.670 (-1.58%)
At Close: Jul 13, 2026
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
07:00am, Wednesday, 01'st Jul 2026
INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW).
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
07:00am, Wednesday, 01'st Jul 2026
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
11:51am, Thursday, 11'th Jun 2026
Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.
Harrow Adds Another Piece To Ophthalmology Strategy
11:42am, Thursday, 11'th Jun 2026
Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic ey
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (
Harrow to Present at William Blair's 46th Annual Growth Stock Conference
07:00am, Wednesday, 27'th May 2026
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present a
HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations
10:13am, Wednesday, 13'th May 2026
MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the
Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript
02:30pm, Tuesday, 12'th May 2026
Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript
Harrow Q1 Earnings Call Highlights
11:11am, Tuesday, 12'th May 2026
Harrow NASDAQ: HROW executives said the company's first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emp
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
07:06pm, Monday, 11'th May 2026
Harrow (HROW) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.38 per share a year ago.
Harrow Announces First Quarter 2026 Financial Results
04:05pm, Monday, 11'th May 2026
First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
11:00am, Monday, 04'th May 2026
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
07:00am, Monday, 27'th Apr 2026
NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its fina
State of Alaska Department of Revenue Acquires 14,065 Shares of Harrow, Inc. $HROW
04:30am, Thursday, 23'rd Apr 2026
State of Alaska Department of Revenue lifted its holdings in shares of Harrow, Inc. (NASDAQ: HROW) by 807.4% in the fourth quarter, according to the company in its most recent disclosure with the Secu
Harrow: Now Is The Buy Time
07:30am, Monday, 20'th Apr 2026
Harrow has delivered a decade-long 40% CAGR in revenue, with robust operating leverage and EBITDA margin expansion. Seasonal weakness in Q1 consistently creates compelling entry points, with share pri
